Exelixis

EXEL Large Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$43.88

-0.36% today

52W: $32.38 – $49.62

52W Low: $32.38 Position: 66.7% 52W High: $49.62

🔗 Compare Brokers

Key Metrics

P/E Ratio

15.78x

Price-to-Earnings

Forward P/E

11.17x

Forward Price/Earnings

P/S Ratio

5.07x

Price-to-Sales

EV/EBITDA

11.43x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$11.8B

Market Capitalization

Revenue Growth

5.6%

YoY Revenue Growth

Profit Margin

33.73%

Net profit margin

ROE

35.53%

Return on Equity

Beta

0.42

Market sensitivity

Short Interest

14.19%

% of float sold short

Avg. Volume

2,778,675

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

18 analysts

Avg. Price Target

$46.83

+6.73% upside

Target Range

$35.00 – $60.00

About the Company

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertensi

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 1,077 Exchange: NMS